Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer

Prostate Cancer and Prostatic Diseases volume 12, pages 333–338 (2009)Cite this article

Abstract

Androgen deprivation therapy (ADT) is the standard of care for metastatic prostate cancer and is increasingly used to treat asymptomatic patients with prostate-specific antigen recurrence after failed primary therapy. Although effective, ADT is associated with multiple adverse effects, many of which are related to the estrogen deficiency that occurs as a result of treatment. These include increased fracture risk, hot flashes, gynecomastia, serum lipid changes and memory loss. By providing clinicians with a greater awareness of the estrogen deficiency induced adverse effects from ADT, they can proactively intervene on the physical and psychological impact these effects have on patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.

    Article  PubMed  Google Scholar 

  2. Pirtskhalaishvili G, Hrebinko RL, Nelson JB . The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9: 295–306.

    Article  CAS  PubMed  Google Scholar 

  3. Heinlein CA, Chang C . Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276–308.

    Article  CAS  PubMed  Google Scholar 

  4. Sharifi N, Gulley JL, Dahut WL . Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238–244.

    Article  CAS  PubMed  Google Scholar 

  5. Higano CS . Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61 (2 Suppl 1): 32–38.

    Article  PubMed  Google Scholar 

  6. Chan JM, Jou RM, Carroll PR . The relative impact and future burden of prostate cancer in the United States. J Urol 2004; 172 (5 Part 2): S13–S16; discussion S17.

    PubMed  Google Scholar 

  7. Flaig TW, Glode LM . Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008; 9: 2829–2841.

    Article  CAS  PubMed  Google Scholar 

  8. Hellerstedt BA, Pienta KJ . The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154–179.

    Article  PubMed  Google Scholar 

  9. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179: 152–155.

    Article  CAS  PubMed  Google Scholar 

  10. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR . Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007; 9: 163–180.

    PubMed  PubMed Central  Google Scholar 

  11. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF . A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996; 11: 150–159.

    Article  CAS  PubMed  Google Scholar 

  12. Manolagas SC . Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115–137.

    CAS  PubMed  Google Scholar 

  13. Manolagas SC, Weinstein RS, Bellido T, Bodenner DL . Opposite effects of estrogen on the life span of osteoblasts/osteocytes vs. osteoclasts in vivo and in vitro: an explanation of the imbalance between formation and resportion in estrogen deficiency. J Bone Miner Res 1999; 14: S169. (Abstract).

    Article  Google Scholar 

  14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731.

    Article  CAS  PubMed  Google Scholar 

  15. Hannan MT, Felson DT, Anderson JJ . Bone mineral density in elderly men and women: results from the Framingham osteoporosis study. J Bone Miner Res 1992; 7: 547–553.

    Article  CAS  PubMed  Google Scholar 

  16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–164.

    Article  CAS  PubMed  Google Scholar 

  17. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K . Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007; 100: 749–754.

    Article  PubMed  Google Scholar 

  18. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL . Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897–7903.

    Article  CAS  PubMed  Google Scholar 

  19. Lee H, McGovern K, Finkelstein JS, Smith MR . Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 16331637.

    Google Scholar 

  20. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410–6417.

    Article  CAS  PubMed  Google Scholar 

  21. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI . Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005–1007.

    Article  PubMed  Google Scholar 

  22. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM . Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007; 22: 1305–1310.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL . Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207–1218.

    Article  CAS  PubMed  Google Scholar 

  24. Karling P, Hammar M, Varenhorst E . Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170–1173.

    Article  CAS  PubMed  Google Scholar 

  25. Schow DA, Renfer LG, Rozanski TA, Thompson IM . Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998; 91: 855–857.

    Article  CAS  PubMed  Google Scholar 

  26. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K . Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004; 11: 735–741.

    Article  PubMed  Google Scholar 

  27. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11 (3): 570–579.

    Article  CAS  PubMed  Google Scholar 

  28. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ . Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920–928.

    Article  CAS  PubMed  Google Scholar 

  29. Ulloa EW, Salup R, Patterson SG, Jacobsen PB . Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer. Psychooncology 2008; 18: 598–605.

    Article  Google Scholar 

  30. Horowitz M, Wilner N, Alvarez W . Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979; 41: 209–218.

    Article  CAS  PubMed  Google Scholar 

  31. Chen AC, Petrylak DP . Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep 2005; 6: 210–216.

    Article  PubMed  Google Scholar 

  32. Autorino R, Perdonà S, D’Armiento M, De Sio M, Damiano R, Cosentino L et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006; 9: 109–114.

    Article  CAS  PubMed  Google Scholar 

  33. Wassersug RJ, Oliffe JL . The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med 2008; 6: 989–1000.

    Article  PubMed  Google Scholar 

  34. Keating NL, O’Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 44484456.

    Google Scholar 

  35. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188–2194.

    Article  CAS  PubMed  Google Scholar 

  36. Mendelsohn ME, Karas RH . The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811.

    Article  CAS  PubMed  Google Scholar 

  37. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S . Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494–498.

    Article  CAS  PubMed  Google Scholar 

  38. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.

    Article  CAS  PubMed  Google Scholar 

  39. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol 2009; 27: 92–99.

    Article  PubMed  Google Scholar 

  40. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

  41. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979–3983.

    Article  PubMed  Google Scholar 

  42. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M et al. Testosterone loss and estradiol administration modify memory in men. J Urol 2006; 175: 130–135.

    Article  CAS  PubMed  Google Scholar 

  43. Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ . Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005; 103: 1381–1387.

    Article  PubMed  Google Scholar 

  44. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005; 64: 290–296.

    Article  CAS  PubMed  Google Scholar 

  45. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M . Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004; 10: 7575–7582.

    Article  CAS  PubMed  Google Scholar 

  46. Eastham JA . Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177: 17–24.

    Article  CAS  PubMed  Google Scholar 

  47. Miyamoto H, Messing EM, Chang C . Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61: 332–353.

    Article  CAS  PubMed  Google Scholar 

  48. Brunton LL, Lazo JS, Parker KL . Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn. McGraw-Hill Companies Inc., 2006.

    Google Scholar 

  49. Gao W, Dalton JT . Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Mol Interv 2007; 7: 10–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Editorial assistance was provided by Michael Malia, PhD. This assistance was funded by GTx Inc.

Author information

Authors and Affiliations

  1. Departments of Surgery (Urology) and Pathology, Durham VA Medical Center and Duke Prostate Center, Duke University School of Medicine, Durham, NC, USA

    S J Freedland

  2. Memorial Sloan-Kettering Cancer Center—Urology, New York, NY, USA

    J Eastham

  3. Atlantic Urology Clinics/Carolina Urologic Research Center, Myrtle Beach, SC, USA

    N Shore

Authors
  1. S J Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Eastham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Shore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S J Freedland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freedland, S., Eastham, J. & Shore, N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 12, 333–338 (2009). https://doi.org/10.1038/pcan.2009.35

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.35

Keywords

This article is cited by

Search

Advanced search

Quick links